Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2003 1
2006 1
2007 3
2008 2
2009 4
2010 5
2011 7
2012 5
2013 5
2014 5
2015 8
2016 3
2017 9
2018 22
2019 20
2020 27
2021 23
2022 14
2023 24
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Cutaneous T cell lymphoma.
Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, Geskin LJ, Quaglino P, Ramelyte E. Dummer R, et al. Among authors: geskin lj. Nat Rev Dis Primers. 2021 Aug 26;7(1):61. doi: 10.1038/s41572-021-00296-9. Nat Rev Dis Primers. 2021. PMID: 34446710 Review.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Among authors: geskin lj. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Olsen EA, et al. Among authors: geskin l. Blood. 2022 Aug 4;140(5):419-437. doi: 10.1182/blood.2021012057. Blood. 2022. PMID: 34758074 Free PMC article.
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Horwitz SM, et al. Among authors: geskin l. Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710. Blood Adv. 2021. PMID: 34507350 Free PMC article. Clinical Trial.
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Olsen EA, et al. Among authors: geskin l. J Clin Oncol. 2011 Jun 20;29(18):2598-607. doi: 10.1200/JCO.2010.32.0630. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576639 Free PMC article.
Monoclonal Antibodies.
Geskin LJ. Geskin LJ. Dermatol Clin. 2015 Oct;33(4):777-86. doi: 10.1016/j.det.2015.05.015. Dermatol Clin. 2015. PMID: 26433849 Free article. Review.
Surgical management of dermatofibrosarcoma protuberans.
Rust DJ, Kwinta BD, Geskin LJ, Samie FH, Remotti F, Yoon SS. Rust DJ, et al. Among authors: geskin lj. J Surg Oncol. 2023 Jul;128(1):87-96. doi: 10.1002/jso.27258. Epub 2023 Mar 31. J Surg Oncol. 2023. PMID: 36999599 Review.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Prince HM, et al. Among authors: geskin l. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. Lancet. 2017. PMID: 28600132
Ustekinumab-associated disseminated verrucae.
Anderson ME, Queen D, Vance SL, Geskin LJ. Anderson ME, et al. Among authors: geskin lj. JAAD Case Rep. 2018 Nov 10;4(10):1030-1033. doi: 10.1016/j.jdcr.2018.08.014. eCollection 2018 Nov. JAAD Case Rep. 2018. PMID: 30456278 Free PMC article. No abstract available.
182 results